Scholarlink

Background <p>SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has attracted attention because it combines genetic features from distinct Omicron descendants and has expanded across multiple regions.SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has&#xa0;attracted attention because it combines genetic features from distinct Omicron&#xa0;descendants and has expanded across multiple regions.</p> Objective <p>To synthesize the current virological, immunological, epidemiological, and clinical evidence on XFG, and to contextualize its public-health significance through comparison with the closely related Omicron-derived lineages JN.1 and NB.1.8.1.…</p> Approach <p>This narrative review integrates available molecular and immune data with&#xa0;surveillance observations and emerging clinical reports, translating technical findings into implications that are relevant for healthcare systems and the people they serve.</p> Key findings <p>Across available datasets, XFG shows modest immune escape and a&#xa0;moderate growth advantage, yet there is no signal of increased clinical severity&#xa0;compared with recent Omicron sublineages. Current evidence supports the continued&#xa0;effectiveness of vaccines and antivirals, reinforcing that incremental viral adaptation is compatible with stable clinical outcomes in immunologically experienced populations.</p> Conclusions <p>XFG exemplifies ongoing, “quiet” SARS-CoV-2 evolution—more consistent with antigenic fine-tuning than a shift toward greater virulence. For individuals, the practical message remains steady: stay updated with vaccination when eligible and seek timely care when at higher risk. For health systems, sustained genomic surveillance, targeted protection of vulnerable groups, and measured risk&#xa0;communication remain central to resilient coexistence with SARS-CoV-2.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Emergence and Characterization of SARS-CoV-2 Variant XFG (“Stratus”): Comparative Virological, Epidemiological, and Public-Health Perspectives

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月10日

查看全文
  • Leena E. Azhar,
  • Dania A. Samkari,
  • Ahmed M. Hassan,
  • Salma M. Alsayed,
  • Esam Ibraheem Azhar

摘要

Background

SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has attracted attention because it combines genetic features from distinct Omicron descendants and has expanded across multiple regions.SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has attracted attention because it combines genetic features from distinct Omicron descendants and has expanded across multiple regions.

Objective

To synthesize the current virological, immunological, epidemiological, and clinical evidence on XFG, and to contextualize its public-health significance through comparison with the closely related Omicron-derived lineages JN.1 and NB.1.8.1.…

Approach

This narrative review integrates available molecular and immune data with surveillance observations and emerging clinical reports, translating technical findings into implications that are relevant for healthcare systems and the people they serve.

Key findings

Across available datasets, XFG shows modest immune escape and a moderate growth advantage, yet there is no signal of increased clinical severity compared with recent Omicron sublineages. Current evidence supports the continued effectiveness of vaccines and antivirals, reinforcing that incremental viral adaptation is compatible with stable clinical outcomes in immunologically experienced populations.

Conclusions

XFG exemplifies ongoing, “quiet” SARS-CoV-2 evolution—more consistent with antigenic fine-tuning than a shift toward greater virulence. For individuals, the practical message remains steady: stay updated with vaccination when eligible and seek timely care when at higher risk. For health systems, sustained genomic surveillance, targeted protection of vulnerable groups, and measured risk communication remain central to resilient coexistence with SARS-CoV-2.